Skip to main content

Adaptive TCR Changes Name to Adaptive Biotechnologies


Adaptive TCR has changed its name to Adaptive Biotechnologies, the company said this week.

The Seattle-based firm provides next-generation sequencing assays under the brand name ImmunoSeq to analyze the adaptive immune system.

Last summer, it raised $5.8 million in a Series B round to grow its services and invest in clinical applications (CSN 6/15/2011).

According to the company's CEO, Chad Robins, the name change better reflects "the full nature and potential" of its products and services, which include T-cell and B-cell receptor sequencing as well as the development of clinical applications for the diagnosis and prognosis of cancer.

Clinical applications include monitoring minimal residual disease in blood-based cancers, more accurate measurements for immune reconstitution after transplantation, and direct measurement of tumor-infiltrating lymphocytes as a prognostic indicator of ovarian cancer. The company is also developing threshold tests to stratify patients into clinical trials, and to predict their response to therapeutics and vaccines.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.